ArticleBMC pulmonary medicine2012
Improving lung cancer survival; time to move on.
Article in BMC pulmonary medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dairy Product, Calcium Intake and Lung Cancer Risk: A Systematic Review with Meta-Analysis.Scientific reports · 2016Pooled it
- Clinical factors influencing long-term survival in a real-life cohort of early stage non-small-cell lung cancer patients in Spain.Frontiers in oncology · 2023Article
- Estimates of incidence, prevalence, mortality, and disability-adjusted life years of lung cancer in Iran, 1990-2019: A systematic analysis from the global burden of disease study 2019.Cancer medicine · 2022Article
- Presence of non-Newtonian fluid in invasive pulmonary mucinous adenocarcinomas impacts fluorescence during intraoperative molecular imaging of lung cancer.European journal of nuclear medicine and molecular imaging · 2022Article
- Association of quality of life with performance status, circadian rhythm, and activity level of lung cancer patients using wearable devices as ambulatory monitoring.Clinical medicine (London, England) · 2022Article
- Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011-2016.Pathology oncology research : POR · 2021Article
- Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From Hungary.Pathology oncology research : POR · 2021Article
- PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer.Frontiers in oncology · 2019Article
- Current Practice in the Management of Pulmonary Nodules Detected on Computed Tomography Chest Scans.Canadian respiratory journal · 2019Article
- Risk factors and mortality of adults with lung cancer admitted to the intensive care unit.Journal of thoracic disease · 2018Article
- Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer.American journal of cancer research · 2018Review
- ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.Molecular pharmaceutics · 2017Article
- AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.American journal of respiratory and critical care medicine · 2017Review
- Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients.Dermatology and therapy · 2017Article
- Diagnostic significance of circulating long noncoding RNA PCAT6 in patients with non-small cell lung cancer.OncoTargets and therapy · 2017Article
- The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
- Recognition of N-glycoforms in human chorionic gonadotropin by monoclonal antibodies and their interaction motifs.The Journal of biological chemistry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the past decades, numerous efforts have been made to decrease the death rate among lung cancer patients. Nonetheless, the improvement in long-term survival has been limited and lung cancer is still a devastating disease. DISCUSSION: With this article we would like to point out that survival of lung cancer could be strongly improved by controlling two pivotal prognostic factors: stage and treatment. This is corresponding with recent reports that show a decrease in lung cancer mortality by screening programs. In addition, modulation of the patient's immune system by immunotherapy either as monotherapy or combined with conventional cancer treatments offers the prospect of tailoring treatments much more precisely and has also been shown to lead to a better response to treatment and overall survival of non-small cell lung cancer patients. SUMMARY: Since only small improvements in survival can be expected in advanced disease with the use of conventional therapies, more research should be focused on lung cancer screening programs and patient tailored immunotherapy with or without conventional therapies. If these approaches are clinically combined in a standard multidisciplinary policy we might be able to advance the survival of patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.